Pharma and Biotech Daily: Eli Lilly Raises Prices, RFK Jr. Supports mRNA Cancer Vaccines

Date: August 18, 2025
Host: Pharma and BioTech News

Episode Overview

Today’s episode delivers a focused roundup of major developments in the pharma and biotech sectors, spotlighting Eli Lilly’s response to U.S. policy changes, RFK Jr.’s shifting perspective on mRNA vaccines for cancer, and a wave of regulatory and business updates. Listeners are updated on new approvals, innovations, site closures, high-profile partnerships, and industry opportunities, keeping them informed of critical events shaping the industry landscape.

Key Discussion Points & Insights

1. Eli Lilly’s Drug Price Increases in Europe

• Main Point: Eli Lilly plans to raise drug prices across Europe, directly responding to the U.S. government's "most favored nation" (MFN) pricing policy.
• Backdrop: The MFN policy, re-introduced by former President Trump, links U.S. drug prices to those in countries paying the lowest price.
• Insight: European markets are expected to absorb higher costs as companies like Eli Lilly adjust in light of global pricing pressures.

Memorable Quote (00:12):

"Eli Lilly plans to raise drug prices in Europe in response to Trump's most favored nation policy."

2. RFK Jr.’s Support for mRNA Cancer Vaccines

• Main Point: Robert F. Kennedy Jr., often critical of vaccines, has publicly supported mRNA-based cancer vaccines.
• Details: After recent skepticism and advocacy for vaccine safety, he now highlights mRNA’s potential for cancer applications.
• Industry Impact: This marks a significant pivot in stance from a prominent public health voice.

Memorable Quote (00:22):

"RFK Jr has expressed support for mRNA cancer vaccines...suggests mRNA vaccines could be effective for cancer."

3. BARDA and Precision Therapeutics Advance

• Main Point: BARDA has terminated some mRNA contracts but, meanwhile, Precision wins FDA approval for a new immunotherapy targeting recurrent respiratory papillomatosis.
• Significance: Despite turbulence in the mRNA contract space, immunotherapy innovations are still advancing.

Memorable Quote (00:27):

"BARDA contracts precision, wins FDA approval for an immunotherapy for recurrent respiratory papillomatosis..."

4. GenScript’s R&D Milestone

• Main Point: GenScript has announced a "new era of innovation," hinting at major advances in biotechnological research and capabilities.

5. Bausch Health’s Site Closure

• Main Point: Bausch Health is closing a major California facility, signaling shifting operational strategies or cost management efforts.

6. Eli Lilly and Superluminal Obesity Partnership

• Main Point: Eli Lilly is collaborating with Superluminal to develop novel treatments for obesity, combining resources and expertise in metabolic disease.

7. Policy & Business Updates

• Trump Delays Tariffs: The current U.S. administration has postponed the introduction of new tariffs, indirectly affecting supply chain and pricing strategies.
• Upcoming Webinars: Highlights include sessions on AI in research, integrated supply chain strategies, and data lake best practices.
• Industry Opportunities: Open positions at Utro Biopharma, Biomarin Pharmaceutical, and AbbVie are spotlighted, reflecting active hiring in the sector.

Notable Quotes & Timestamps

• Eli Lilly’s Price Move:
  "Eli Lilly plans to raise drug prices in Europe in response to Trump's most favored nation policy." — [00:12]
• RFK Jr. on mRNA Vaccines:
  "RFK Jr has expressed support for mRNA cancer vaccines. After cutting mRNA, BARDA contracts precision, wins FDA approval for an immunotherapy..." — [00:22]
• Kennedy’s Vaccine Stance:
  "...Kennedy revives a childhood vaccine safety group and suggests mRNA vaccines could be effective for cancer." — [00:29]
• Industry Movements:
  "GenScript announces a new era of innovation, Bausch Health closes a California site, and Eli Lilly partners with Superluminal for obesity treatments." — [00:32]

Additional Industry Updates

• Webinars: Focused on AI in research, integrated supply chain strategies, and leveraging data lakes for pharma.
• Jobs:
  • Utro Biopharma
  • Biomarin Pharmaceutical
  • AbbVie

These points reveal dynamic changes and opportunities within the industry.

Conclusion

This episode provides a concise, high-impact briefing on major news relevant to professionals in pharma and biotech. The host’s clear focus on emerging science, business policy, and job market activity ensures listeners are prepared for ongoing changes in the sector.